OXiGENE Announces Positive Phase Ib Update of CA4P With Radiotherapy

OXiGENE has announced that a clinical investigator studying the company's lead vascular targeting agent, Combretastatin A4 Prodrug (CA4P), has noted that CA4P is well-tolerated when combined with radiotherapy thus far in the Phase Ib portion of a planned Phase Ib/II combination trial of the compound in patients with advanced cancer.

Patients with inoperable, advanced non-small cell lung cancer (NSCLC), or prostate adenocarcinoma, who are eligible to receive radiotherapy (RT) were enrolled. The first two cohorts (six patients per cohort) had NSCLC, and received RT over three weeks. Patients in the third and fourth cohorts had prostate cancer, and received RT over four weeks. Patients in the first and third cohorts received a single dose of CA4P at the completion of radiation treatment; patients in the second and fourth cohorts received weekly CA4P for the duration of their RT.

The study authors conclude that "CA4P is well-tolerated when combined with RT. There was no increase in acute or late RT reaction, and no accumulation of toxicity with repeated doses."